The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why I rate DERM stock a Buy.

BOSTON - Ironwood Pharmaceuticals , Inc. (NASDAQ: NASDAQ:IRWD), currently trading at $3.72 with a market capitalization of ...

Pharmaceuticals announced a streamlined strategic focus on advancing and realizing the potential of apraglutide for the ...

Trump's pick for HHS Secretary faces questions from the left and right over his health stances. But will that stop his ...

Medicine may not be an exact science, but precision is crucial for patient care. That’s why the presence of unknown particles ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

According to the Dickerson’s Pharmacy mission, they are “Saving patients time and money and cherishing friendships in Bladen ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...